KRAS and pancreatic ductal adenocarcinoma: In their protocol, owing to the high prevalence of KRAS mutations in pancreatic ductal adenocarcinoma (PDAC), the organoids are first placed in an EGF-depleted condition to enrich cancer organoids with an autonomously active EGFR-RAS pathway.